From: Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma
Clinical factor | 3-year OS | |||
---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
HR (95% CI) | P value | HR (95% CI) | P value | |
Age | 1.204 | 0.557 | Ā | Ā |
ā(<ā60 vs. ā„ā60Ā years) | (0.649ā2.235) | Ā | Ā | Ā |
Gender | 0.869 | 0.775 | Ā | Ā |
ā(Male vs. female) | (0.331ā2.282) | Ā | Ā | Ā |
TMEM176A | 2.388 | 0.027* | 2.370 | 0.025* |
ā(Methylation vs. unmethylation) | (1.102ā5.175) | Ā | (1.116ā5.034) | Ā |
HBV infection | 0.592 | 0.142 | Ā | Ā |
ā (YES vs. NO) | (0.294ā1.191) | Ā | Ā | Ā |
Liver cirrhosis | 1.360 | 0.401 | Ā | Ā |
ā(Yes vs. no) | (0.664ā2.784) | Ā | Ā | Ā |
Tumor size | 1.184 | 0.670 | Ā | Ā |
ā(ā¤ā5Ā cm vs. >ā5Ā cm) | (0.544ā2.580) | Ā | Ā | Ā |
Number of lesions | 0.902 | 0.793 | Ā | Ā |
ā(1 vs. ā„ā1) | (0.419ā1.944) | Ā | Ā | Ā |
Differentiation | 2.212 | 0.020* | 1.989 | 0.015* |
ā(Well or moderate vs. poor) | (1.133ā4.320) | Ā | (1.140ā3.470) | Ā |
TNM stage | 1.150 | 0.724 | Ā | Ā |
ā(Stage I + stage II vs. stage III + stage IV) | (0.528ā2.505) | Ā | Ā | Ā |
Lymph node metastasis | 1.184 | 0.670 | Ā | Ā |
ā(Negative vs. positive) | (0.544ā2.580) | Ā | Ā | Ā |
Vessel cancerous embolus | 0.444 | 0.025* | 0.441 | 0.006** |
ā(Negative vs. positive) | (0.219ā0.902) | Ā | (0.245ā0.794) | Ā |